Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

result, our ability to respond to the comments raised by the FDA regarding our manufacturing process may exceed the timeframe we currently anticipate and we cannot assure that we will be capable of generating the data requested by the FDA in the timeframe we anticipate. In addition, the FDA may request additional data, require additional conformance batches, delay any decision past the time frames anticipated by us, or deny the approval of the industrial scale manufacturing process. If the manufacturing capacity expansion projects at Sanquin are delayed, or do not result in the capacity we anticipate, if Sanquin cannot obtain necessary regulatory approvals for the contemplated facility expansions in the time frames we anticipate or if we are not able to manufacture the anticipated volume of product at the existing scale, we may not be able to satisfy patient demand. Our inability to obtain adequate product supplies to satisfy our patient demand may create opportunities for our competitors and we will suffer a loss of potential future revenues. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K for the year ended December 31, 2011, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. VIROPHARMA INCORPORATEDSelected Financial InformationConsolidated Statements of Operations:Three months endedTwelve months ended(in thousands, except per share data)

December 31,December 31,2011201020112010(unaudited)Revenue:Net product sales

$ 145,575$ 121,623$ 544,374$ 439,012Costs and Expenses:Cost of sales (excluding amortization of product rights)

19,68317,93479,97661,288Research and development

12,70710,46066,47739,613Selling, general and administrativ
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- BioClinica®, Inc., a leading provider of outsourced clinical ... its experts are speaking at the 20th Annual ... held September 28 to October 1 in ... the innovative Compass technology, a risk-based monitoring ... earlier this year, is up for the Technology ...
(Date:9/17/2014)... PITTSBURGH , Sept. 17, 2014 ... maker of MD-Cu 29 antimicrobial copper, announces Gilmour ... points to the first EPA-registered antimicrobial solid touch surface ... copper is a reasonably priced surface that kills greater ... 2 hours of exposure. 1 ...
(Date:9/17/2014)... , Sept. 17, 2014 RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced that it has been granted ... Trademark Office on its unique delivery system for ... to phagocytic cells for the treatment of diseases ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... , Jan. 12 Novavax, Inc. (Nasdaq: ... pre-clinical safety and efficacy study of its RSV vaccine candidate ... support an Investigational New Drug (IND) application to advance this ... into clinical development.  This vaccine candidate is composed of recombinant ...
... ... a standalone Windows® desktop application for viewing eCTD submissions created for any region. ... Marlborough, MA (PRWEB) January 12, ... for the life sciences industry, today announced the release of Datafarm VUE, a new addition ...
... ... VA, will discuss practical approaches to President Obama’s challenges to "find the needle in ... ... connect the dots” on the Christmas bomber in his recent address to the Nation. ...
Cached Biology Technology:NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 2NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 3NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 4NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 5Datafarm Releases New Desktop-based Application for Multi-region Viewing of eCTD Submissions: Datafarm VUE 2NDIA's Biometrics Conference to Address Practical Approaches to the President's Challenge of 'Connecting the Dots' and Implementing $1B for New and Additional Security 2
(Date:9/16/2014)... school biology taught us that we inherit certain traits ... you could change how these genes play out by ... diet? That,s exactly what a team of researchers ... proposed through their research of epigenetics research. , ... chemically modifying DNA and histone proteins, which prevent permanent ...
(Date:9/16/2014)... own bacterial identity. That,s the conclusion of University of ... the genetic fingerprints of bacteria on 57 species of ... demonstrates for the first time that host plants from ... very different microbial communities on their leaves," said lead ... the UO,s Institute of Ecology and Evolution who is ...
(Date:9/16/2014)... 10-km diameter chunk of rock hit the Yukatan peninsula near ... force of 100 teratons of TNT. It left a crater ... global earthquakes and volcanism are widely accepted to have wiped ... the mammals. But what happened to the plants on which ... from the University of Arizona reveals that the meteorite impact ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... DALLAS May 20, 2008 Mutations in two ... the brain involved in sleep create a human-like insomnia ... found. The findings may help scientists better understand the ... This is one of the most dramatic ...
... exposure to chemicals is on the increase. From food ... with potentially-toxic substances could be affecting our health ... Nottingham are set to take part in one of ... on female mammals. Part of the Reproductive Effects of ...
... CITY Researchers have been unable to build an ... dream of ultrafast optical computers. But now, University of ... photonic crystals with the ideal, diamond-like structure: They are ... beetle from Brazil. It appears that a simple ...
Cached Biology News:Gene mutations in mice mimic human-like sleep disorder, UT Southwestern researchers find 2Do chemicals in the environment affect fertility? 2The photonic beetle 2The photonic beetle 3The photonic beetle 4The photonic beetle 5
...
Healthy animals 10-32 weeks of age, mixed gender and breed; collected on wet ice following USDA guidelines, using Alsevers solution at 1:2 dilution...
... The Zero Blunt TOPO ... the fastest and easiest ... than or equal to95%) ... products amplified with proofreading ...
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
Biology Products: